Back to top
more

Anthera Pharmaceuticals (ANTH)

(Delayed Data from OTC)

$0.00 USD

0.00
NA

0.00 (0.00%)

Updated Apr 24, 2024 03:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Endo's Troubles Continue to Dent Performance in 2017?

by Zacks Equity Research

2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.

    AstraZeneca's Lung Cancer Drug Tagrisso Approved in China

    by Zacks Equity Research

    AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.

      Merrimack (MACK) Starts Enrollment in Solid Tumors Study

      by Zacks Equity Research

      Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.

        Shire (SHPG) Rare Disease Drug Gets Fast Track Designation

        by Zacks Equity Research

        Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).

          OvaScience, Inc. (OVAS) Looks Good: Stock Up 9.6% Higher

          by Zacks Equity Research

          OvaScience, Inc. (OVAS) shares rose almost 10% in the last trading session.

            Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2%

            by Zacks Equity Research

            Enzo Biochem, Inc. (ENZ) shares rose above 5% in the last trading session.

              AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher

              by Zacks Equity Research

              AveXis, Inc. (AVXS) shares rise above 15% in the last trading session.

                Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%

                by Zacks Equity Research

                Fortress Biotech, Inc. (FBIO) moved big last session, as its shares rose over 8% on the day.

                  Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase

                  by Zacks Equity Research

                  Shares of Valeant Pharmaceuticals (VRX) were up after investor ValueAct Capital management increased its stake in the company to 5.2%.

                    Implied Volatility Surging for Anthera (ANTH) Stock Options

                    by Zacks Equity Research

                    Options traders are pricing in a big move for Anthera (ANTH) shares as it has huge implied volatility.

                      Shire's (SHPG) Cinryze Label Expanded for Pediatric Use

                      by Zacks Equity Research

                      Shire plc (SHPG) announced that the European Commission (EC) has approved a label extension for drug Cinryze for use in pediatrics.

                        Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA

                        by Zacks Equity Research

                        Endo International plc (ENDP) announced that the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees had consented that the benefits of reformulated Opana ER no longer outweigh its risks.

                          Inovio (INO) Q4 Loss Wider than Expected; Shares Decline

                          by Zacks Equity Research

                          Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.

                            Rexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4%

                            by Zacks Equity Research

                            Rexahn Pharmaceuticals, Inc. (RNN) moved big last session, as its shares rose above 5% on the day.

                              VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y

                              by Zacks Equity Research

                              VIVUS Inc. (VVUS) reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period

                                Tirthankar Chakraborty headshot

                                New Strong Buy Stocks for March 8th

                                by Tirthankar Chakraborty

                                Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                                  Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data

                                  by Zacks Equity Research

                                  Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.

                                    Are Options Traders Betting on a Big Move in Anthera Pharmaceuticals (ANTH) Stock?

                                    by Zacks Equity Research

                                    Investors in Anthera Pharmaceuticals, Inc. (ANTH) need to pay close attention to the stock based on moves in the options market lately.